Protalix BioTherapeutics, Inc.

PLX • Biotechnology

$2.67

▲ +0.05 (+2.10%)

Precio actual

ResultadosÚltimo reporte: 31 mar 2026

PERFIL DE MAYOR RIESGOPrecauciónConfianza: 70%

Perfil cuantitativo — no constituye una recomendación de inversión.

Perfil cuantitativo — no constituye una recomendación de inversión.Metodología

Tesis del análisis: Conviene actuar con cautela. Los ratios recientes muestran debilidades que pueden limitar el retorno si los fundamentales no mejoran.

Capitalización

$221.74M

Crecimiento

—

Flujo de caja

1/5

Tendencia

Volatile

Evidencia

Nivel de deuda manejable · 0.17Liquidez saludable · 2.51Tendencia de crecimiento negativaRentabilidad débil

Datos financieros hasta: 31 mar 2026, 12:00 a.m. UTCÚltima actualización de earnings: 13 may 2026, 12:00 a.m. UTCÚltima actualización del perfil: 5 ago 2026, 2:36 p.m. UTC

Resumen de la compañía

Valoración, calidad, fortaleza financiera, momentum y datos de analistas.

Price$2.67

Change2.10%

Shares Out83.05M

Market Cap$221.74M

Enterprise Value$171.38M

52W Range1.36 - 3.19

Beta0.01

P/E14.46

P/S2.90

P/B3.30

P/FCF15.15

EV/Sales2.24

Price$2.67

Change2.10%

Shares Out83.05M

Market Cap$221.74M

Enterprise Value$171.38M

52W Range1.36 - 3.19

Beta0.01

P/E14.46

P/S2.90

P/B3.30

P/FCF15.15

EV/Sales2.24

EV/EBITDA8.04

EV/FCF11.71

Earnings Yield6.91%

FCF Yield6.60%

Dividend Yield0.00%

Gross Margin47.85%

Oper. Margin-10.43%

Profit Margin-12.52%

Debt/Eq0.17

Current Ratio2.51

Quick Ratio1.54

Target$6.00

Target Upside124.72%

Target Median$6.00

Target Range6.00 - 6.00

Volume354.69K

Avg Volume744.67K

EPS Surprise0.23

ADN de inversión

Qué tan fuerte luce esta compañía para inversionistas de largo plazo

de 100

Calidad del negocio

Márgenes, ventaja competitiva, retornos

22/100

Fortaleza financiera

Deuda, caja, estabilidad

76/100

Potencial de crecimiento

Ingresos y expansión

20/100

Atractivo del precio

Barata o cara hoy

80/100

Por qué este puntaje▼

Nivel de deuda manejable · 0.17Liquidez saludable · 2.51Tendencia de crecimiento negativaRentabilidad débil

Analyst view

Analyst sentiment and price target

PLX

Analyst sentiment

Based on 7 analyst votes · 2026-09-05

86/100

Bullish

Hold

Bearish

Precio objetivo

2026-09-05

Bajo

$6.00

Promedio

$6.00

Mediana

$6.00

Alto

$6.00

Resumen de la compañía

IPO: 5/15/1998

Industria: Biotechnology

P/B i: 3.30

Deuda / Patrimonio i: 0.17

Margen operativo: -10.43%

Margen neto: -12.52%

ROE i: -

ROIC: -

Salud financiera

Puntaje15 / 20

Deuda / Patrimonio: 0.17

Ratio corriente: 2.51

Ratio rápido: 1.54

Estado: Good

Transacciones internas

Actividad reciente de ejecutivos e insiders

Mamlok Gilad

Transacción: 08/24/2025

OTRO

Cambio

Precio

Not reported

Presentación

04/27/2026

Tipo

OTRO

Bashan Dror

Transacción: 12/19/2025

COMPRA

Cambio

+56,000

Precio

$1.81

Presentación

12/23/2025

Tipo

COMPRA

Bar-Shalev Amos

Transacción: 11/18/2025

VENTA

Cambio

-168

Precio

$1.87

Presentación

11/19/2025

Tipo

VENTA

Insider	Tipo	Cambio	Precio	Transacción	Presentación
Mamlok Gilad	OTRO	0	Not reported	08/24/2025	04/27/2026
Bashan Dror	COMPRA	+56,000	$1.81	12/19/2025	12/23/2025
Bar-Shalev Amos	VENTA	-168	$1.87	11/18/2025	11/19/2025
Bashan Dror	COMPRA	+340,000	$1.64	09/03/2025	09/04/2025
Bashan Dror	COMPRA	+195,000	Not reported	09/03/2025	09/04/2025
Naos Yaron	COMPRA	+50,000	$1.64	09/03/2025	09/04/2025
Naos Yaron	COMPRA	+25,000	Not reported	09/03/2025	09/04/2025
Bar-Shalev Amos	COMPRA	+7,500	Not reported	09/03/2025	09/04/2025
Bar-Shalev Amos	COMPRA	+15,000	$1.64	09/03/2025	09/04/2025
Ben Zvi Shmuel	COMPRA	+7,500	Not reported	09/03/2025	09/04/2025
Ben Zvi Shmuel	COMPRA	+15,000	$1.64	09/03/2025	09/04/2025
Schwartz Aharon	COMPRA	+7,500	Not reported	09/03/2025	09/04/2025
Elze Christian	COMPRA	+7,500	Not reported	09/03/2025	09/04/2025
Schwartz Aharon	COMPRA	+15,000	$1.64	09/03/2025	09/04/2025
Elze Christian	COMPRA	+15,000	$1.64	09/03/2025	09/04/2025
Boudes Pol F	COMPRA	+7,500	Not reported	09/03/2025	09/04/2025
Boudes Pol F	COMPRA	+15,000	$1.64	09/03/2025	09/04/2025
Melincoff Gwen A	COMPRA	+7,500	Not reported	09/03/2025	09/04/2025
Forster Eliot	COMPRA	+7,500	Not reported	09/03/2025	09/04/2025
Forster Eliot	COMPRA	+15,000	$1.64	09/03/2025	09/04/2025

Sobre la compañía

Protalix BioTherapeutics, Inc.

Protalix BioTherapeutics, Inc., a biopharmaceutical company, engages in the development, production, and commercialization of recombinant therapeutic proteins based on the ProCellEx plant cell-based protein expression system. The company provides Elelyso for the treatment of Gaucher disease; and Elfabrio for the treatment of adult patients with a confirmed diagnosis of Fabry disease. It is also developing PRX-115, a plant cell expressed recombinant PEGylated Uricase, which is in Phase 2 trial for the treatment of gout; and PRX-119, a plant cell expressed PEGylated recombinant human DNase I product candidate for the treatment of neutrophil extracellular traps diseases. The company has agreements and partnerships with Pfizer; Fundação Oswaldo Cruz; and Chiesi Farmaceutici S.p.A. Protalix BioTherapeutics, Inc. has strategic partnership with Secarna Pharmaceuticals GmbH & Co KG. The company is headquartered in Hackensack. New Jersey.

Fuente - Link

Competidores

CDXS CHRS GNFT IVVD MDWD NTHI OABI SGMO SLS TARA

Tamaño = capitalización · color = línea del gráfico

Rendimiento de peers · 1A

Top performers + empresa seleccionada

Ultimas Noticias

Protalix BioTherapeutics, Inc. (PLX) Q2 2026 Earnings Call Transcript

Seeking Alpha

Protalix BioTherapeutics Reports Second Quarter 2026 Financial and Business Results

Company to host conference call and webcast today at 8:00 a.m. EDT Revenues from selling goods increased to $19.8 million in the second quarter of 2026, up $4.4 million from the second quarter of 2025, driven primarily by sales of Elfabrio® Total revenue climbed to $53.6 million, year to date, from $25.8 million for the same period in 2025, which includes the previously reported $25.0 million Chiesi milestone payment Year-to-date, the Company achieved profitability with a net income of $22.1 million The Company reiterates full-year 2026 guidance of $78.0 million to $83.0 million in total revenue PRX-115 Phase 2 study continues to advance as planned, with top-line results anticipated in the second half of 2027 Cash, cash equivalents, and short-term bank deposits were $40.7 million as of June 30, 2026, providing sufficient capital to fund ongoing operations including the Phase 2 RELEASE clinical trial of PRX-115 CARMIEL, Israel, Aug. 12, 2026 /PRNewswire/ -- Protalix BioTherapeutics, Inc. (NYSE American: PLX), a biopharmaceutical company focused on the discovery, development, production, and commercialization of innovative therapeutics for rare diseases with significant unmet needs, today reported financial results for the second quarter ended June 30, 2026, and provided a business and clinical update.

PRNewsWire

Protalix BioTherapeutics to Announce Second Quarter 2026 Financial Results and Business Update on August 12, 2026

Company to host conference call and webcast at 8:00 a.m. EDT CARMIEL, Israel, Aug. 5, 2026 /PRNewswire/ -- Protalix BioTherapeutics, Inc. (NYSE American: PLX), a biopharmaceutical company focused on the discovery, development, production, and commercialization of innovative therapeutics for rare diseases with significant unmet needs, today announced that it will release its financial results for the quarter ended June 30, 2026 and provide a business update on August 12, 2026.

PRNewsWire

Sorpresas de ganancias

Período	Estimado	Real	Sorpresa
2026-05-13	-0.01	0.22	0.23
2026-03-18	0.01	-0.07	-0.08
2025-11-13	0.06	0.03	-0.03
2025-08-14	0.03	0.00202	-0.02798
2025-05-09	0.08	-0.05	-0.13
2025-03-17	0.07	0.09	0.02
2024-11-14	0.06	0.03	-0.03
2024-08-14	-0.00857	-0.03	-0.02143
2024-05-10	-0.02	-0.06	-0.04
2024-03-14	-0.03	-0.07	-0.04
2023-11-06	-0.07	-0.04	0.03
2023-08-07	0.02897	0.21	0.18103